心臟生物植入設備的全球市場的預測:各類型，各用途，各終端用戶，各國，企業分析(2024年～2032年)

全球心臟生物植入器材市場分析

全球心臟生物植入設備市場規模預計將從 2023 年的 371.3 億美元增至 2032 年的 691.2 億美元，2024 年至 2032 年複合年增長率為 7.15%。心臟生物植入物的興起是由於人口老化、心血管疾病發生率相對較高、生物材料科學的進步以及全球人口越來越喜歡微創手術等因素。

心臟生物植入設備的前景

心臟生物植入裝置是調節和治療心臟容器內疾病的小型化衛生系統。此類設備包括心律調節器、除顫器、生物假體心臟瓣膜和心室輔助裝置 (VAD)。心律調節器透過使用可以控制心跳的電訊號來幫助控制不規則的心跳。另一方面，當發現醫學上嚴重的心律不整時，除顫器用於對心臟進行電擊。機械心臟瓣膜是合成瓣膜，可取代有缺陷或患病的天然瓣膜，並保持血液以正確的方式流經心臟。心室輔助裝置透過補充心臟的泵血功能來幫助患有嚴重心臟衰竭的患者，特別是等待心臟移植的患者。

這些心臟生物植入裝置透過填補心臟組織的間隙來改善心臟病患者的生活品質。因此，它可以緩解症狀，改善心臟功能，並減少致命事件的機會。心律調節器和除顫器用於幫助您實現適當的節律並避免中風或心臟衰竭等明顯問題。生物人工心臟瓣膜可增加體內血液循環，減輕心臟負擔。心室輔助裝置為末期心臟衰竭患者提供所需的支持，增加他們在等待心臟移植期間的生存機會和整體健康狀況。新技術的發展正在為全球數千萬患者帶來光明和美好前景。

推動心臟生物植入設備市場的因素

世界各地的老化

全球人口老化是心臟生物植入物市場的主要成長因素之一。心血管疾病包括心臟衰竭、心律不整和心臟瓣膜疾病，其發生率隨著年齡的增長而增加。 65 歲以上的患者更容易罹患各種需要侵入性手術的心臟疾病，例如心律調節器、除顫器，甚至瓣膜。因此，老年人口數量不斷增加，對這些維持生命的發明的需求不斷增加，市場不斷擴大。此外，醫療領域的新技術創新和更好的健康結構使得向老齡化人口的關鍵部分供應這些設備成為可能，從而推動了市場的發展。

技術進步

隨著醫療領域新技術的引入，心臟生物植入市場正在不斷發展。無引線心律調節器、MRI 相容設備和微創手術等新技術正在提高這些植入物的安全性和性能，並提高患者的舒適度。具有遠端監控功能的便攜式設備可以持續評估患者狀況並及時進行幹預，以防止住院和不良結果。此外，生物材料合成和組織工程技術的進步有助於提高現有生物人工心臟瓣膜的強度和性能並擴大其用途。這些技術進步正在成為市場驅動力，因為它們提供了更好的治療設施並擴大了心臟生物植入物的使用。

心血管疾病盛行率增加

心血管疾病盛行率的上升是整個心臟生物植入物市場的主要成長動力。世界各地的心臟病病例不斷增加，因為許多人吃不健康的食物、很少運動、久坐的生活方式、體重超重和感到壓力。隨著越來越多的患者被診斷出心臟衰竭、心律不整和 CAD 等疾病，對心臟生物植入物來解決這些問題的需求也在增加。供應商還指出，政府和衛生部門正在推動提高認識活動和早期診斷計劃，以增加識別心臟病患者的可能性，這可能會促使用於治療疾病的植入設備的出現，這有助於擴大對設備的需求。

本報告研究了全球心臟生物植入設備市場，並提供了市場成長驅動因素和課題、市場佔有率以及主要參與者的分析。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

• 成長促進因素
• 課題

第5章 心臟生物植入設備市場

第6章 市場佔有率

• 各類型
• 各用途
• 各終端用戶
• 各國

第7章 類型

• 心律調節器
• ICD(植入式心臟整流去顫器)
• CRT(心臟再同步化治療)

第8章 用途

• 心律不整
• 心肌缺血
• 急性心肌梗塞
• 心臟衰竭

第9章 終端用戶

• 醫院
• 門診病人手術中心
• 心導管檢驗室
• 其他

第10章 國家

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 比利時
  • 荷蘭
  • 瑞士
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 泰國
  • 馬來西亞
  • 印尼
  • 菲律賓
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東·非洲
  • 南非
  • 沙烏地阿拉伯
  • 土耳其
  • 阿拉伯聯合大公國
• 其他地區

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企業的分析

• F. Hoffman-La Roche
• Eurofins Scientific
• Illumina, Inc.
• Natera Inc.
• Abbott Laboratories
• Thermo Fisher Scientific
• Quest Diagnostics
• Agilent Technologies

Global Cardiac Bio Implant Devices Market Analysis

The market for the Cardiac Bio Implant Devices will be US$ 69.12 billion by 2032 from US$ 37.13 billion in 2023 with a Compound Annual Growth Rate of 7.15% between 2024 and 2032. Cardiac bioimplant arises from causes-such as the aging population, relatively higher incidences of cardiovascular diseases, developments in biomaterial science and an ever-rising global population with a penchant for procedures that do not require much intrusion.

Cardiac Bio Implant Devices Outlooks

Cardiac bioimplant devices are miniaturized health systems that regulate and cure disease of the heart containers. Such devices include pacemakers, defibrillators, bio-prosthetic heart valves as well as ventricular assist devices (VADs). Pacemakers therefore assist in controlling irregular heartbeats using electrical signals that are capable of controlling the heartbeat. In turn, defibrillators are used to apply electrical shocks to the heart if it identifies medically serious forms of the arrhythmia. Mechanical heart valves are synthetic and replace the natural ones that are either faulty or have a disease, and keep the blood flowing in the right way through the heart VADs assist patients with severe heart failure help by supplementing the pumping function of the heart especially to those awaiting on heart transplants.

These cardiac bio-implant devices improve the quality of life of patients with cardiac issues by filling the gap in heart tissue. It therefore relieves symptoms, enhances the function of the heart, and decreases the probability of fatal occurrences. Pacemakers and defibrillators are used to approach a proper rhythm and avoid such conspicuous issues as stroke or failure of the heart. Bio-prosthetic heart valves enhance the circulation of blood in the body meaning less workload to the heart. VADs offer much-needed support to the patients with end stage heart failure, boosting the patients' survival rates and general well-being while waiting for the heart transplant. New technological development gives a silver lining and better prospects for tens of millions of patients globally.

Driving Forces for Cardiac Bio Implant Devices Market

Aging population worldwide

The global ageing population is one of the main growth stimulants for the cardiac bio implant devices market. Cardiovascular diseases include heart failure, arrhythmias, and valvular heart diseases, and their occurrence raises with age. Patients above 65 years are prone to suffer different heart diseases that need invasive procedures like pacemakers, defibrillators, and even valves. This has ensured that there is an increase in the number of elderly people, and hence the need for these lives supporting inventions hence increasing the market. Also, new innovations in the medical field and better health structures make the delivery of these devices to a crucial demographic of the aging population feasible, thereby boosting its market.

Technological Advancements

The market for Cardiac bio-implant devices is advancing due to the introduction of the latest technology in the medical field. New technologies including leadless pacemakers, MRI compatible devices, and Minimal invasive surgery these have enhanced the safety and performance of these implants and also the comfort of the patients. The portable devices with remote monitoring permits a constant assessment of the conditions of the patients and their timely intervention to prevent hospitalizations and worsened results. Also, technological improvements in the synthesis of the biomaterials and tissue engineering helped in improving the strength and performance of existing bio-prosthetic heart valves hence extending their use. These are the technological advancements that are acting as the driving force for the market as it provides better treatment facilities and has expanded the usage of cardiac bio-implants.

Rising Incidence of Cardiovascular Diseases

Rising incidence of cardiovascular diseases is a key factor that will foster the growth of the overall market for cardiac bio implant devices. Most people consume unhealthy foods, hardly exercise, lead a sedentary life, are overweight and stressed which are leading them to increased cases of heart diseases globally. As a large number of the patients are diagnosed with diseases like heart failure, arrhythmia, or CAD, the need for troubled solutions, cardiac bio-implants, increases as well. Suppliers also find governments and healthcare sectors promoting awareness campaigns and early diagnosis programs so as to increase the chances of identifying patients with the cardiac diseases, contributing to the enhanced requirement for the implantable devices to manage the diseases.

Favourable Reimbursement Policies

The reimbursement policies in particular and the insurance coverage of the cardiac bio-implant procedures are key factors that have huge impacts on the growth of the market. Different developed countries have health insurance schemes and government healthcare programs that cater for a number of costs pertaining to cardiac implants. It assists in alleviating the costs of treatment and extends the possibility of great-quality cardiac treatment to more people. Also, prices have been influenced by the shift in health care reforms and outcomes-based care which include the use of high quality cardiac implant devices. It is these employment policies and financial incentive that contributes to the market by ensuring these invaluable pieces of equipment's are easily within reach.

Asia Pacific Cardiac Bio Implant Devices Market

With the increased rate of cardiovascular disease, increasing population, and higher health care expenses, the Asia Pacific cardiac bio implant devices market is progressing at a higher rate. Administrations of countries such as China, India, and Japan are major players in opening up the market due to the advancement of healthcare facilities and increased awareness of cardiac diseases. Some of these drivers include; technological progress and development such as minimally invasive surgeries and improved bio-prosthetic heart valves. More so, the availably of the devices is boosting through friendly government policies and take up of insurance products. This market is further augmented by the rising focus on the early screening and prevention that enhance the sales of pacemakers, defibrillators, and other cardio devices in the region.

Cardiac Bio Implant Devices Company Analysis

The top companies in the Cardiac Bio Implant Device industry are F. Hoffman-La Roche, Eurofins Scientific, Illumina, Inc., Natera, Inc., Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Agilent Technologies.

Cardiac Bio Implant Devices Company News

Roche signed a $2.7 billion cash deal in December 2023 to acquire US-based Carmot Therapeutics.

In February 2021, Medtronic introduced the TYRX Absorbable Antibacterial Envelope. This unique, one-time-use envelope has antimicrobial qualities and supports implanted neurostimulators or cardiac implantable electrical devices.

Type- Market breakup in 3 viewpoints:

1. Pacemaker

2. ICDs

3. CRT

Application- Market breakup in 4 viewpoints:

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End User- Market breakup in 4 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Country - Market breakup of 25 Countries:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

6. Rest of the world

All the key players have been covered from 4 Viewpoints:

• Business Overview
• Product Portfolio
• Recent Development & Strategies
• Revenue Analysis

Key Players Analysis:

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiac Bio Implant Devices Market

6. Market Share

• 6.1 By Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Type

• 7.1 Pacemaker
• 7.2 ICDs (Implantable Cardioverter Defibrillator)
• 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

• 8.1 Arrhythmias
• 8.2 Myocardial Ischemia
• 8.3 Acute Myocardial Infarction
• 8.4 Heart Failure

9. End-User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Cardiac Catheterization Laboratories
• 9.4 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Switzerland
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 Philippines
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 MEA
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 Turkey
  • 10.5.4 UAE
• 10.6 Rest of the World

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 F. Hoffman-La Roche
  • 13.1.1 Overview
  • 13.1.2 Product Portfolio
  • 13.1.3 Recent Development
  • 13.1.4 Revenue Analysis
• 13.2 Eurofins Scientific
  • 13.2.1 Overview
  • 13.2.2 Product Portfolio
  • 13.2.3 Recent Development
  • 13.2.4 Revenue Analysis
• 13.3 Illumina, Inc.
  • 13.3.1 Overview
  • 13.3.2 Product Portfolio
  • 13.3.3 Recent Development
  • 13.3.4 Revenue Analysis
• 13.4 Natera Inc.
  • 13.4.1 Overview
  • 13.4.2 Product Portfolio
  • 13.4.3 Recent Development
  • 13.4.4 Revenue Analysis
• 13.5 Abbott Laboratories
  • 13.5.1 Overview
  • 13.5.2 Product Portfolio
  • 13.5.3 Recent Development
  • 13.5.4 Revenue Analysis
• 13.6 Thermo Fisher Scientific
  • 13.6.1 Overview
  • 13.6.2 Product Portfolio
  • 13.6.3 Recent Development
  • 13.6.4 Revenue Analysis
• 13.7 Quest Diagnostics
  • 13.7.1 Overview
  • 13.7.2 Product Portfolio
  • 13.7.3 Recent Development
  • 13.7.4 Revenue Analysis
• 13.8 Agilent Technologies
  • 13.8.1 Overview
  • 13.8.2 Product Portfolio
  • 13.8.3 Recent Development
  • 13.8.4 Revenue Analysis